96 related articles for article (PubMed ID: 17578651)
1. Polyamine contents in current foods: a basis for polyamine reduced diet and a study of its long term observance and tolerance in prostate carcinoma patients.
Cipolla BG; Havouis R; Moulinoux JP
Amino Acids; 2007 Aug; 33(2):203-12. PubMed ID: 17578651
[TBL] [Abstract][Full Text] [Related]
2. Polyamine reduced diet (PRD) nutrition therapy in hormone refractory prostate cancer patients.
Cipolla BG; Havouis R; Moulinoux JP
Biomed Pharmacother; 2010 May; 64(5):363-8. PubMed ID: 20106631
[TBL] [Abstract][Full Text] [Related]
3. Polyamine-reduced diet in metastatic hormone-refractory prostate cancer (HRPC) patients.
Cipolla B; Guillí F; Moulinoux JP
Biochem Soc Trans; 2003 Apr; 31(2):384-7. PubMed ID: 12653644
[TBL] [Abstract][Full Text] [Related]
4. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
5. Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer.
Azuma H; Sakamoto T; Kiyama S; Ubai T; Kotake Y; Inamoto T; Takahara K; Nishimura Y; Segawa N; Katsuoka Y
Am J Clin Oncol; 2008 Apr; 31(2):188-94. PubMed ID: 18391605
[TBL] [Abstract][Full Text] [Related]
6. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
Xie W; Nakabayashi M; Regan MM; Oh WK
Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of PC-Spes2 in advanced hormone refractory prostate cancer.
Shabbir M; Love J; Montgomery B
Oncol Rep; 2008 Mar; 19(3):831-5. PubMed ID: 18288423
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of quality of life of patients with hormone-refractory prostate cancer after gene therapy.
Terao S; Shirakawa T; Acharya B; Miyata M; Hinata N; Tanaka K; Takenaka A; Hara I; Naoe M; Fuji K; Okegawa T; Higashihara E; Kamidono S; Fujisawa M; Gotoh A
Anticancer Res; 2009 May; 29(5):1533-7. PubMed ID: 19443362
[TBL] [Abstract][Full Text] [Related]
9. The impact of prostate size on urinary quality of life indexes following laparoscopic radical prostatectomy.
Levinson AW; Bagga HS; Pavlovich CP; Mettee LZ; Ward NT; Link RE; Su LM
J Urol; 2008 May; 179(5):1818-22. PubMed ID: 18353375
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
[TBL] [Abstract][Full Text] [Related]
11. The prevalence of erectile dysfunction among Brazilian men screened for prostate cancer.
Paranhos M; Antunes A; Andrade E; Freire G; Srougi M
BJU Int; 2009 Oct; 104(8):1130-3. PubMed ID: 19426190
[TBL] [Abstract][Full Text] [Related]
12. Lycopene for advanced hormone refractory prostate cancer: a prospective, open phase II pilot study.
Schwenke C; Ubrig B; Thürmann P; Eggersmann C; Roth S
J Urol; 2009 Mar; 181(3):1098-103. PubMed ID: 19150092
[TBL] [Abstract][Full Text] [Related]
13. Cancer-related pain and quality of life in prostate cancer patients: assessment using the Functional Assessment of Prostate Cancer Therapy.
Fujimura T; Takahashi S; Kume H; Takeuchi T; ; Kitamura T; Homma Y
Int J Urol; 2009 May; 16(5):522-5. PubMed ID: 19383037
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy for patients with localized hormone-refractory prostate cancer: results of the Patterns of Care Study in Japan.
Sasaki T; Nakamura K; Ogawa K; Onishi H; Okamoto A; Koizumi M; Shioyama Y; Mitsumori M; Teshima T;
BJU Int; 2009 Nov; 104(10):1462-6. PubMed ID: 19522869
[TBL] [Abstract][Full Text] [Related]
15. Tolerance and efficacy of a polyamine-deficient diet for the treatment of perioperative pain.
Estebe JP; Degryse C; Rezzadori G; Dimache F; Daccache G; Le Naoures A; Belbachir A; Schoeffler P; Sérandour AL
Nutrition; 2017 Apr; 36():33-40. PubMed ID: 28336105
[TBL] [Abstract][Full Text] [Related]
16. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
Rosenthal SA; Bae K; Pienta KJ; Sobczak ML; Asbell SO; Rajan R; Kerlin KJ; Michalski JM; Sandler HM;
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):672-8. PubMed ID: 18990504
[TBL] [Abstract][Full Text] [Related]
17. Dietary modification in patients with prostate cancer on active surveillance: a randomized, multicentre feasibility study.
Parsons JK; Newman VA; Mohler JL; Pierce JP; Flatt S; Marshall J
BJU Int; 2008 May; 101(10):1227-31. PubMed ID: 18218061
[TBL] [Abstract][Full Text] [Related]
18. Clinical events in prostate cancer lifestyle trial: results from two years of follow-up.
Frattaroli J; Weidner G; Dnistrian AM; Kemp C; Daubenmier JJ; Marlin RO; Crutchfield L; Yglecias L; Carroll PR; Ornish D
Urology; 2008 Dec; 72(6):1319-23. PubMed ID: 18602144
[TBL] [Abstract][Full Text] [Related]
19. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
Bong GW; Clarke HS; Hancock WC; Keane TE
Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
[TBL] [Abstract][Full Text] [Related]
20. The short-term and long-term effects of radical prostatectomy on lower urinary tract symptoms.
Slova D; Lepor H
J Urol; 2007 Dec; 178(6):2397-400; discussion 2400-1. PubMed ID: 17936841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
